Objective To explore the feasibility for therapy of spinal cord injury （SCI） by genetic engineering neural stem cell （NSC） modified by lentiviral vector. Methods Following the construction of the genetic engineering NSC modified by lentivirus to secrete both neurotrophic factor-3 （NT-3） and green fluorescence protein （GFP）

hemisection of spinal cord at the level of T

10 was performed in 56 adult Wistar rats that were randomly divided into 4 groups （n=14）

namely 3 therapeutic groups and 1 control group. The therapeutic groups were dealed with NSC

genetic engineering NSC

and concentrated lentiviral supernatant which carries both GFP and NT-3

respectively. Then used fluorescence microscope to detect the transgenic expression in vitro and in vivo

migration of the grafted cells in vivo

and used the Basso

Beattie

and Bresnahan （BBB） open-field locomotor test to assess the recovery of function. Results The transplanted cells could survive for long time in vivo and migrate for long distance. The stable transgenic expression could be detected in vivo. The hindlimb function of the injured rats in 3 therapeutic groups

especially those dealed with genetic engineering NSC

improved obviously. Conclusion It is feasible to combine NSC with lentivirus for the repair of SCI. NSC modified by lentivirus to deliver NT-3

acting as a source of neurotrophic factors and function cell in vivo

has the potential to participate in spinal cord repair.